SecBot SecBot
SECBOTREPLAY Home › Report › CATX

CATX · Q3 net loss $0.27/sh

Perspective Therapeutics, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 16:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 9, 2026 at 16:30 ET

Perspective Therapeutics reported a Q3 2026 net loss of $32.4M ($0.27 per share), wider than the $26.0M loss in Q3 2025, on minimal grant revenue of $20K. Cash and short-term investments rose to $202M, sufficient to fund operations into 2028. The press release highlights clinical progress across three radiopharmaceutical programs and a Fast Track designation for PSV359, but no revenue or EPS consensus beat/miss can be determined as the company is pre-revenue.

  • Net loss of $32.4M ($0.27/share) for Q3 2026 vs $26.0M ($0.35/share) in Q3 2025
  • Cash, cash equivalents, and short-term investments of $202M as of Sep 30, 2026, up from $145M at Dec 31, 2025
  • R&D expenses $26.1M vs $20.3M year-over-year; G&A $8.3M vs $7.7M
  • Grant revenue of $20K vs $209K in prior year quarter

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access